Fresenius Kabi USA, LLC has recalled 14,016 vials of Fluorouracil Injection, USP (5 g / 100 mL), a prescription medication used in cancer treatment. This recall affects both the Fresenius Kabi brand and the NOVAPLUS brand due to the presence of visible glass particulate matter found in the vials. Consumers should be aware that using an injectable drug containing glass particles can lead to serious health complications, such as inflammation or damage to blood vessels and vital organs. You should contact your healthcare provider or pharmacist immediately if you have received this medication.
The injection of glass particulates can cause local irritation, inflammation, or the blockage of blood vessels, which may lead to serious events like pulmonary embolism or damage to organs such as the heart and kidneys.
Drug recall baseline remedy
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES ยท Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.